Literature DB >> 29470692

Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.

R J Rodenburg1, P E Hanssens2, V K Y Ho3, L V Beerepoot4.   

Abstract

Melanoma brain metastases (MBM) are common in patients with stage IV disease. For Gamma Knife radiosurgery (GKRS) on MBM, risk scores such as RPA and melanoma-GPA aid to identify prognostic subgroups. This study aimed to validate the overall survival (OS) risk score developed by Chowdhury et al. in our center's patient cohort. A total of 104 MBM patients were treated with GKRS between 1/1/2002 and 31/12/2014 in our institution. Patients were categorized according to RPA, melanoma-GPA and Chowdhury OS score. The Kaplan-Meier method was used to estimate overall survival, and predicted survival probabilities were calculated for calibration. Cox proportional hazards regressions were performed to identify additional risk factors. Overall, median follow-up time was 80 months, while median OS (mOS) after GKRS was 6 months. Stratified according to the Chowdhury OS score, mOS in the high, medium and low risk group was 3.4, 7.1, and 10.0 months, respectively. The addition of other patient or disease characteristics to the Chowdhury OS model did not improve its performance. The C-index of the melanoma-GPA was 0.46 while the Chowdhury OS had an index of 0.67. In comparison with the RPA and melanoma-GPA, the Chowdhury OS score more accurately distinguished between separate risk groups among patients with MBM treated with GKRS. Contrary to the original study by Chowdhury, follow-up time was sufficient here for the low-risk group to reach the mOS time of 10 months.

Entities:  

Keywords:  Chowdhury overall survival score; Gamma Knife radiosurgery; Melanoma brain metastasis

Mesh:

Year:  2018        PMID: 29470692     DOI: 10.1007/s11060-018-2808-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article.

Authors:  Donald N Liew; Hideyuki Kano; Douglas Kondziolka; David Mathieu; Ajay Niranjan; John C Flickinger; John M Kirkwood; Ahmad Tarhini; Stergios Moschos; L Dade Lunsford
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

Review 2.  Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.

Authors:  Chirag G Patil; Katie Pricola; J Manuel Sarmiento; Sachin K Garg; Andrew Bryant; Keith L Black
Journal:  Cochrane Database Syst Rev       Date:  2017-09-25

3.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

4.  Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.

Authors:  Amparo Wolf; Sayyad Zia; Rashika Verma; Anna Pavlick; Melissa Wilson; John G Golfinos; Joshua S Silverman; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2016-02-06       Impact factor: 4.130

5.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 6.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

Review 7.  Systemic therapies for melanoma brain metastases: which drug for whom and when?

Authors:  Sangeetha Ramanujam; Dirk Schadendorf; Georgina V Long
Journal:  Chin Clin Oncol       Date:  2015-06

8.  A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

Authors:  Ibiayi Dagogo-Jack; Michael Lanfranchi; Justin F Gainor; Anita Giobbie-Hurder; Donald P Lawrence; Alice T Shaw; Ryan J Sullivan
Journal:  J Immunother       Date:  2017-04       Impact factor: 4.456

Review 9.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

10.  External validation of a Cox prognostic model: principles and methods.

Authors:  Patrick Royston; Douglas G Altman
Journal:  BMC Med Res Methodol       Date:  2013-03-06       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.